A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy
Abstract Background Selectively replicating herpes simplex virus-2 (HSV-2) vector is a promising treatment for cancer therapy. The insertion of multiple transgenes into the viral genome has been performed to improve its oncolytic activity. Methods Herein, we simultaneously constructed five “armed” o...
Main Authors: | Han Hu, Siqi Zhang, Linkang Cai, Haixiao Duan, Yuying Li, Junhan Yang, Yang Wang, Biao Liu, Shuang Dong, Zhizheng Fang, Binlei Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-04-01
|
Series: | Virology Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12985-022-01795-1 |
Similar Items
-
Oncolytic herpes simplex virus and immunotherapy
by: Wenqing Ma, et al.
Published: (2018-12-01) -
Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
by: Bangxing Hong, et al.
Published: (2022-01-01) -
Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
by: Yoshiaki Yura
Published: (2017-05-01) -
Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells
by: Dhaval S. Sanchala, et al.
Published: (2017-05-01) -
Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
by: Mingming Hu, et al.
Published: (2023-11-01)